^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Rituxan Hycela (rituximab/hyaluronidase) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:...Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide
Secondary therapy:
cyclophosphamide + fludarabine IV + cyclophosphamide intravenous
